## Core Concept
Rofecoxib and indomethacin are both nonsteroidal anti-inflammatory drugs (NSAIDs), but they belong to different subclasses. Rofecoxib is a **coxib**, specifically a **COX-2 inhibitor**, which selectively inhibits the cyclooxygenase-2 enzyme. Indomethacin, on the other hand, is a **non-selective NSAID**, inhibiting both COX-1 and COX-2 enzymes.

## Why the Correct Answer is Right
Rofecoxib, as a COX-2 inhibitor, offers the advantage of reduced gastrointestinal toxicity compared to non-selective NSAIDs like indomethacin. This is because COX-1 is primarily responsible for protective prostaglandins in the stomach, while COX-2 is more involved in inflammation. Therefore, by selectively inhibiting COX-2, rofecoxib decreases the risk of gastrointestinal side effects.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because it does not accurately reflect the primary difference between rofecoxib and indomethacin.
- **Option B:** This option is incorrect because, although both drugs can provide analgesia and anti-inflammatory effects, the question seems to focus on their pharmacological profiles rather than therapeutic uses.
- **Option C:** This option might seem plausible but is incorrect because it does not accurately represent the key distinction between these two drugs.
- **Option D:** This option is incorrect because it inaccurately describes the comparative effects or mechanisms of rofecoxib and indomethacin.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **COX-2 inhibitors**, like rofecoxib, were developed to reduce the gastrointestinal side effects associated with long-term use of non-selective NSAIDs. However, due to concerns about increased risk of cardiovascular events, the use of COX-2 inhibitors like rofecoxib has been limited.

## Correct Answer Line
**Correct Answer: C.**